Patents by Inventor Maria E. GACZYNSKA

Maria E. GACZYNSKA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR PREDICTING DRUG RESPONSIVENESS IN SAMPLES FROM CANCER SUBJECTS
    Publication number: 20220308062
    Abstract: Described herein are compositions and methods for predicting drug responsiveness in cellular samples from cancer subjects. Described herein are compositions and methods that can help determine treatment options and select subjects for clinical trials.
    Type: Application
    Filed: May 7, 2020
    Publication date: September 29, 2022
    Inventors: Josephine Taverna, Chia-Nung Hung, Tim Huang, Nameer Kirma, Daniel Dearmond, Chiou-Min Wang, Meizhen Chen, Pawel A. Osmulski, Maria E. Gaczynska
  • Methods for the treatment of cancer metastasis
    Patent number: 11020383
    Abstract: Provided herein are methods of preventing or treating cancer metastasis by administering an allosteric ligand of proteasomes. Further provided are methods of monitoring the efficacy of treatment with an allosteric ligand for reducing metastatic potential of a tumor.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: June 1, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Pawel A. Osmulski, Maria E. Gaczynska
  • METHODS FOR THE TREATMENT OF CANCER METASTASIS
    Publication number: 20200121661
    Abstract: Provided herein are methods of preventing or treating cancer metastasis by administering an allosteric ligand of proteasomes. Further provided are methods of monitoring the efficacy of treatment with an allosteric ligand for reducing metastatic potential of a tumor.
    Type: Application
    Filed: April 19, 2018
    Publication date: April 23, 2020
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Pawel A. OSMULSKI, Maria E. GACZYNSKA
  • Allosteric inhibitors of proteasome and methods of use thereof
    Patent number: 10167259
    Abstract: The present invention relates generally to novel allosteric regulators of proteasome activity, methods for preparation and use, and pharmaceutical compositions thereof. Specifically piperidine-2-carboxylic acid derivatives containing 1-oxo-aroyl group and a lipophilic ester side chain are disclosed as allosteric inhibitors of proteasome 2S activity, and as therapeutic agents for the treatment of proteasome-associated disorders in a subject.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: January 1, 2019
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Pawel A. Osmulski, Maria E. Gaczynska
  • Rapamycin analogs targeting proteasome function in the treatment of cancer
    Patent number: 9918968
    Abstract: The invention provides for treatment of cancers using a rapamycin analog, optionally including bortezomib. In particular, the invention addresses the treatment of bortezomib-resistant cancers using seco-rapamycin and optionally a second proteasome inhibitor. This invention relates to oncology and medicine, and more particularly to treatment of cancer. In particular, rapamycin analogs such as seco-rapamycin may be used advantageously to target the proteasome in cancer cells, optionally in conjunction with proteasome inhibitors such as bortezomib.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: March 20, 2018
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maria E. Gaczynska, Pawel A. Osmulski
  • NOVEL ALLOSTERIC INHIBITORS OF PROTEASOME AND METHODS OF USE THEREOF
    Publication number: 20160152567
    Abstract: The present invention relates generally to novel allosteric regulators of proteasome activity, methods for preparation and use, and pharmaceutical compositions thereof. Specifically piperidine-2-carboxylic acid derivatives containing 1-oxo-aroyl group and a lipophilic ester side chain are disclosed as allosteric inhibitors of proteasome 2S activity, and as therapeutic agents for the treatment of proteasome-associated disorders in a subject.
    Type: Application
    Filed: June 13, 2014
    Publication date: June 2, 2016
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SY STEM
    Inventors: Pawel A. OSMULSKI, Maria E. GACZYNSKA
  • RAPAMYCIN ANALOGS TARGETING PROTEASOME FUNCTION IN THE TREATMENT OF CANCER
    Publication number: 20150328192
    Abstract: The invention provides for treatment of cancers using a rapamycin analog, optionally including bortezomib. In particular, the invention addresses the treatment of bortezomib-resistant cancers using seco-rapamycin and optionally a second proteasome inhibitor. This invention relates to oncology and medicine, and more particularly to treatment of cancer. In particular, rapamycin analogs such as seco-rapamycin may be used advantageously to target the proteasome in cancer cells, optionally in conjunction with proteasome inhibitors such as bortezomib.
    Type: Application
    Filed: December 24, 2013
    Publication date: November 19, 2015
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maria E. GACZYNSKA, Pawel A. OSMULSKI